Evidence map›Paper›PMID 27001317›Full record

Trial reportPediatric dermatology

Effects of a New Emollient-Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis.

Pascale Bianchi, Jennifer Theunis, Christiane Casas, Cecile Villeneuve, Annalisa Patrizi, Chloe Phulpin, Adeline Bacquey, Daniel Redoulès, Valerie Mengeaud, Anne-Marie Schmitt

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Emollients and moisturisers for eczema.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Skin Microbiome and its Interplay with the Environment.American journal of clinical dermatology · 2020
    Review
  13. Article
  14. Article
  15. Clinical approach to the patient with refractory atopic dermatitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018
    Review
  16. Anti-inflammatory and immunomodulatory effects ofClinical, cosmetic and investigational dermatology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Pascale BianchiEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Jennifer TheunisEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Christiane CasasEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Cecile VilleneuveEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Annalisa PatriziDepartment of Dermatology, University of Bologna, Bologna, Italy.
Chloe PhulpinEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Adeline BacqueyEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Daniel RedoulèsEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Valerie MengeaudEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Anne-Marie SchmittEuropean Center for Skin Research, Pierre Fabre Dermo-Cosmétique, Toulouse, France.
Skin Research Center · FRPierre Fabre (France) · FRUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe use of emollients is widely recommended for the management of atopic dermatitis (AD), especially between flares. An imbalance of skin microflora is suspected of playing a key role in exacerbations of AD. Our aim was to evaluate the effect of a new emollient balm on clinical parameters (SCORing Atopic Dermatitis [SCORAD], xerosis, pruritus), skin barrier function (transepidermal water loss and loricrin, filaggrin, corneodesmosin, and involucrin expression], skin microflora biodiversity, and Staphylococcus aureus and Staphylococcus epidermidis balance in children with mild AD.

methodsFifty-four children (1-4 yrs old) were enrolled in this randomized, controlled study. Subjects applied a hygiene product and the emollient balm (emollient group, n = 28) or the hygiene product only (control group, n = 26) twice a day for 28 days.

resultsWe found improvement in favor of the emollient group in SCORAD (p < 0.001), pruritus (p = 0.06), and xerosis (p = 0.06) after 28 days of application. Moreover, transepidermal water loss decreased in the emollient group by 34% (p = 0.06) and involucrin expression by 37% (p = 0.001) at day 28 from baseline in association with improvement in barrier function, whereas other barrier-specific proteins did not vary. S. aureus increased significantly in the control group only (6.5 times, p = 0.01), whereas S. epidermidis remained stable in both groups. The Shannon index (H' = 2.3) did not vary with treatment in either group.

conclusionTwice-daily application of a new emollient balm in children with mild AD protected the skin from S. aureus proliferation and preserved microflora biodiversity.

Indexed as

Child, PreschoolDermatitis, AtopicEmollientsFilaggrin ProteinsHumansInfantSkinStaphylococcus aureusStaphylococcus epidermidisEmollientsFilaggrin ProteinsFLG protein, human

Identifiers

PMID27001317
PMCPMC5071726
OpenAlexW2307159860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.